Bispecific antibodies (bsAbs) are engineered to simultaneously engage two distinct antigens or separate epitopes on the same target. This dual-binding capability unlocks novel therapeutic mechanisms—such as T-cell redirection, receptor cross-linking, and synergistic signaling blockade—that traditional monoclonal antibodies cannot achieve. As the clinical landscape for cancer immunotherapy and autoimmune treatments rapidly expands, securing a reliable manufacturing pipeline for these complex molecules is critical.

Pronewbio brings over a decade of specialized bioprocessing expertise to overcome the inherent challenges of bsAb production, including chain mispairing, aggregation, and low expression yields. We offer a highly customizable, end-to-end platform for the expression and purification of virtually any bispecific architecture.

Our Platform Advantages

• Architectural Versatility: We possess the technical capability to successfully express and assemble a diverse array of complex bispecific formats, tailored precisely to your therapeutic strategy.
• Accelerated Timelines: Our optimized mammalian expression systems enable a rapid transition from in silico gene sequence to purified protein in as few as three weeks.
• High-Throughput Screening Capacity: Powered by automated workflows, our facility supports a monthly throughput of up to 1,000 unique bsAb constructs, ideal for large-scale candidate screening.
• Demonstrated Expertise: Backed by 10 years of recombinant protein experience, our team consistently delivers over 1,000 custom antibody projects annually, ensuring robust troubleshooting and process optimization.

Common bsAb Structures Supported

We routinely handle the specific folding and purification requirements for both major classes of bispecifics:

• Fc-Bearing Bispecifics: Engineered for extended serum half-life and optimal Fc-mediated effector functions (ADCC/CDC). Examples include Knob-into-Hole (KiH), CrossMab, and DVD-Ig formats.

• Fc-Free Bispecifics: Designed for rapid clearance, reduced steric hindrance, and superior solid-tumor penetration. Examples include Tandem scFvs, Diabodies, and BiTEs.

End-to-End Service Workflow

Our comprehensive production pipeline is designed for transparency, speed, and uncompromising quality.

Phase 1: Sequence Optimization & Gene Synthesis (Optional | 1 Week)

• Proprietary codon optimization to maximize translational efficiency in mammalian hosts.
• De novo synthesis of target genes.

Phase 2: Vector Construction (~1 Week)

• Seamless cloning into Pronewbio's high-expression vectors.
• Rigorous sequence verification and endotoxin-free plasmid extraction.

Phase 3: Expression & Purification (~2 Weeks)

• High-density transient transfection in optimized HEK293 or CHO suspension cell lines.
• Multi-step chromatographic purification tailored to the specific BsAb format to eliminate homodimers and aggregates.

Phase 4: Stringent QC & Final Delivery (3 Days)

• Comprehensive biophysical characterization to confirm purity, concentration, and molecular weight.
• Deliverables: Highly purified bsAb, detailed Quality Control analytics report, and the cloned expression vectors.